MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41591-026-04471-x

Медицинская библиотека · Nature medicine · 2026

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Raab Marc S, Weinhold Niels, Kortüm K Martin, Krönke Jan, Fenk Roland, Weisel Katja, Podola Lilli, Bertsch Uta, Brobeil Alexander, Mersi Julia, Huhn Stefanie, Arlinghaus Ryan, Hundemer Michael, Bohl Stephan R, Mai Elias K, Schub Natalie, Waldschmidt Johannes, Bassermann Florian, Müller-Tidow Carsten, Heuck Christoph, Sakabedoyan Caline, Khan Josephine, Ershova Elena, Koster Bas D, Engelhardt Monika, Hänel Mathias, Salwender Hans, Teipel Raphael, Goldschmidt Hartmut, Einsele Hermann, Rasche Leo, GMMG-HD10/DSMM-XX (MajesTEC-5) investigators

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

Advancements in frontline therapies have substantially improved outcomes in newly diagnosed multiple myeloma (NDMM); however, many patients will not achieve deep responses and will relapse. Teclistamab, a BCMA×CD3 bispecific antibody, in combination with daratumumab, has demonstrated strong efficacy in relapsed/refractory multiple myeloma versus standard of care as early as first relapse. This ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) study evaluates teclistamab-based regimens in transplant-eligible NDMM. In this prespecified pooled analysis of three cohorts, 49 patients received teclistamab/daratumumab/lenalidomide (Tec-DR; arms A and A1) or Tec-DR with bortezomib (Tec-DVR; arm B). Primary endpoints were incidence and severity of adverse events (AEs) and serious AEs; secondary endpoints included overall response rate (ORR), minimal residual disease (MRD) negativity and MRD-negative complete response (CR). The current analysis spans the induction and autologous stem cell transplantation phases until the premaintenance timepoint. Grade 3 or 4 treatment-emergent AEs (TEAEs) occurred in 91.8% (45/49); most were hematologic (lymphopenia (59.2%; 29/49), neutropenia (59.2%; 29/49) and leukopenia (18.4%; 9/49)). No grade 5 TEAEs were reported. Serious AEs occurred in 55.1% (27/49); pyrexia (12.2% (6/49)) was most common. Any-grade and grade 3 or 4 infections occurred in 81.6% (40/49) and 36.7% (18/49), respectively, the most common grade 3 or 4 infections being COVID-19 and pneumonia (6.1% (3/49) each). Cytokine release syndrome occurred in 67.3% (33/49); all were grade 1 or 2, all resolved and none led to discontinuation of any study treatment. No treatment-related immune effector cell-associated neurotoxicity syndrome (ICANS) events occurred. Across arms, the MRD-negative CR rate was 91.8% (45/49) by the premaintenance timepoint; the MRD negativity rate was 100% in evaluable samples at postinduction cycle 3 (1 × 10-5 (46/46)), cycle 6 (1 × 10-5 (46/46) and 1 × 10-6 (46/46)) and premaintenance (1 × 10-5 (40/40)); the ORR was 100% (49/49). Total median stem cell yield was 8.1 × 106 per kg. Data support the feasibility of Tec-D(V)R induction in transplant-eligible NDMM, with a consistent safety profile compared with individual regimen components and notable early MRD negativity rates. ClinicalTrials.gov identifier: NCT05695508 .

Для цитирования: Raab Marc S, Weinhold Niels, Kortüm K Martin, Krönke Jan, Fenk Roland, Weisel Katja, Podola Lilli, Bertsch Uta, Brobeil Alexander, Mersi Julia, Huhn Stefanie, Arlinghaus Ryan, Hundemer Michael, Bohl Stephan R, Mai Elias K, Schub Natalie, Waldschmidt Johannes, Bassermann Florian, Müller-Tidow Carsten, Heuck Christoph, Sakabedoyan Caline, Khan Josephine, Ershova Elena, Koster Bas D, Engelhardt Monika, Hänel Mathias, Salwender Hans, Teipel Raphael, Goldschmidt Hartmut, Einsele Hermann, Rasche Leo, GMMG-HD10/DSMM-XX (MajesTEC-5) investigators. Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.. Nature medicine. 2026. DOI: 10.1038/s41591-026-04471-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.